RxDoctor Payments Data

Victor Lopez de Mendoza, MD

Nephrology · Miami, FLNPI 1073667770

Payments from drug & device makers

$5,438in general payments, 2019–2025

Across 69 payments — averaging $78.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Medtronic$2K
  • Boston Scientific$487
  • Novo Nordisk$232
  • Johnson & Johnson$124
  • Akebia Therapeutics Inc$119
  • plus $183 from 4 others

What the payments were for

  • Food & beverage$5,38999%
  • Education$491%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,438 in reported general payments places this provider in the 70th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$284,474
Medicare patients
695
Services billed
2,282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide18$33,679
Sevelamer Carbonate78$25,010
LokelmaSodium Zirconium Cyclosilicate30$19,828
VeltassaPatiromer Calcium Sorbitex14$13,653
EliquisApixaban25$10,779
XareltoRivaroxaban22$6,251
Cinacalcet Hcl16$2,579
Midodrine Hcl23$2,171
Calcium Acetate36$1,968
Gabapentin27$887
Bumetanide23$808
Nifedipine ErNifedipine13$704
Escitalopram Oxalate27$519
Latanoprost13$465
Famotidine22$435

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma$119$19,82830 claims
PfizerEliquis$18$10,77925 claims
Johnson & JohnsonXarelto$124$6,25122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 756 nephrology providers in Florida.

Other nephrology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →